What is he best known for?
The fields of study he is best known for:
His primary areas of study are Pseudomonas exotoxin, Immunotoxin, Molecular biology, Exotoxin and Antibody.
His study in Pseudomonas exotoxin is interdisciplinary in nature, drawing from both Cytotoxic T cell, Microbiology and Virology.
His Immunotoxin study combines topics in areas such as Cancer research and Immunotherapy.
His Molecular biology research includes themes of Epitope, Epidermal growth factor, Fusion protein and Escherichia coli.
His work in Exotoxin addresses issues such as Stereochemistry, which are connected to fields such as Microbial toxins, Polyethylene glycol and Glutathione.
David J. FitzGerald works mostly in the field of Antibody, limiting it down to topics relating to Antigen and, in certain cases, Cancer cell, Diphtheria toxin, Cell biology, Cell surface receptor and Internalization.
His most cited work include:
- Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia (483 citations)
- A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin (480 citations)
- Immunotoxin Therapy of Cancer (408 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Pseudomonas exotoxin, Immunotoxin, Molecular biology, Exotoxin and Biochemistry.
His Pseudomonas exotoxin research is under the purview of Recombinant DNA.
His Immunotoxin study integrates concerns from other disciplines, such as Cancer research and Antigen.
As a part of the same scientific study, he usually deals with the Molecular biology, concentrating on Cytotoxicity and frequently concerns with Pharmacology.
The concepts of his Exotoxin study are interwoven with issues in Epitope, In vitro and Mutant.
His work on Amino acid, Cleavage, Furin and Protease is typically connected to Elongation factor as part of general Biochemistry study, connecting several disciplines of science.
He most often published in these fields:
- Pseudomonas exotoxin (58.80%)
- Immunotoxin (43.20%)
- Molecular biology (36.40%)
What were the highlights of his more recent work (between 2012-2021)?
- Immunotoxin (43.20%)
- Cancer research (17.60%)
- Pseudomonas exotoxin (58.80%)
In recent papers he was focusing on the following fields of study:
David J. FitzGerald mainly focuses on Immunotoxin, Cancer research, Pseudomonas exotoxin, Molecular biology and Cancer cell.
His research on Immunotoxin concerns the broader Antibody.
His Cancer research research includes elements of Recombinant immunotoxin and Pancreatic cancer.
His Pseudomonas exotoxin study incorporates themes from Cell, Antigen, Pharmacology and Furin.
David J. FitzGerald has included themes like Epitope, Apoptosis, B cell and Cytotoxicity in his Molecular biology study.
His study looks at the relationship between Cancer cell and fields such as Tyrosine kinase, as well as how they intersect with chemical problems.
Between 2012 and 2021, his most popular works were:
- Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia (360 citations)
- Immunotoxins for leukemia (85 citations)
- Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts (41 citations)
In his most recent research, the most cited papers focused on:
David J. FitzGerald mainly investigates Immunotoxin, Molecular biology, Pseudomonas exotoxin, Apoptosis and Antibody.
His Immunotoxin research incorporates elements of Cytotoxic T cell and Keyhole limpet hemocyanin.
As a part of the same scientific family, David J. FitzGerald mostly works in the field of Molecular biology, focusing on Cytotoxicity and, on occasion, Transferrin receptor, Caspase 7 and Caspase 3.
David J. FitzGerald focuses mostly in the field of Pseudomonas exotoxin, narrowing it down to matters related to Furin and, in some cases, Tyrosine kinase, Cancer cell and Cancer research.
His work in the fields of Apoptosis, such as Programmed cell death and Unfolded protein response, overlaps with other areas such as BH3 Mimetic ABT-737.
His work in Antibody addresses subjects such as Immunotherapy, which are connected to disciplines such as Antigen and Chronic lymphocytic leukemia.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
